Adagrasib Induces 68% ORR in Subset of Patients With KRAS G1

Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.

Related Keywords

Copenhagen , Køavn , Denmark , Switzerland , Geneva , Genè , Monte Rosa , Daiichi Sankyo , Adagrasib Krazati , Roche Genentech , Eli Lilly , Lowe Center , Pfizer , Novartis , Astrazeneca , Chen Huang Center , Belfer Center , Cancers At Dana Farber Cancer Institute , Gatekeeper Pharmaceuticals , Boehringer Ingelheim , Oncology Annual Congress , European Lung Cancer Congress , Thoracic Oncology , Applied Cancer Science , Dana Farber Cancer Institute , Lung Cancer Conference , Agilent Resolution , Oncology Annual , Revolution Medicines , Takeda Oncology , Silicon Therapeutics , Allorion Therapeutics , Accutar Biotech , Scorpion Therapeutics , Frontier Medicines , Oncology Annual Meeting , Adagrasib , Patients With Kras G12c Mutated Non Small Cell Lung Cancer , Krystal 1 Trial , Nct03785249 , Pasia Jänne , D , Phd , European Lung Cancer Conference ,